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abstract
Diet high in dairy products is inversely associated with body mass index, 
risk of metabolic syndrome and prevalence of type 2 diabetes in several 
populations. Also a number of intervention studies support the role of in-
creased dairy intake in the prevention and treatment of obesity. Dairy cal-
cium has been suggested to account for the effect of dairy on body weight, 
but it has been repeatedly shown that the effect of dairy is superior to the 
effect of supplemental calcium. Dairy proteins are postulated to either en-
hance the effect of calcium or have an independent effect on body weight, 
but studies in the area are scarce. The aim of this study was to evaluate the 
potential of dairy proteins and calcium in the prevention and treatment of 
diet-induced obesity in C57Bl/6J mice. The effect of dairy proteins and 
calcium on the liver and adipose tissue was also investigated in order to 
characterise the potential mechanisms explaining the reduction of risk for 
metabolic syndrome and type 2 diabetes.
A high-calcium diet (1.8%) in combination with dietary whey protein 
inhibited body weight and fat gain and accelerated body weight and fat loss 
in high-fat-fed C57Bl/6J mice during long-term studies of 14 to 21 weeks. 
α-lactalbumin, one of the major whey proteins, was the most effective whey 
protein fraction showing significantly accelerated weight and fat loss dur-
ing energy restriction and reduced the amount of visceral fat gain during 
ad libitum feeding after weight loss. The microarray data suggest sensitisa-
tion of insulin signalling in the adipose tissue as a result of a calcium-rich 
whey protein diet. Lipidomic analysis revealed that weight loss on whey 
protein-based high-calcium diet was characterised by significant decreases 
in diabetogenic diacylglycerols and lipotoxic ceramide species.
The calcium supplementation led to a small, but statistically signifi-
cant decrease in fat absorption independent of the protein source of the 
diet. This augments, but does not fully explain the effects of the studied 
diets on body weight. A whey protein-containing high-calcium diet had a 
protective effect against a high-fat diet-induced decline of β3-adrenergic 
receptor expression in adipose tissue. In addition, a high-calcium diet 
with whey protein increased the adipose tissue leptin expression which is 
abstract
11abstract
decreased in this obesity-prone mouse strain. These changes are likely to 
contribute to the inhibition of weight gain. The potential sensitisation of 
insulin signalling in adipose tissue together with the less lipotoxic and dia-
betogenic hepatic lipid profile suggest a novel mechanistic link to explain 
why increased dairy intake is associated with a lower prevalence of meta-
bolic syndrome and type 2 diabetes in epidemiological studies. 
Taken together, the intake of a high-calcium diet with dairy proteins has 
a body weight-lowering effect in high-fat-fed C57Bl/6J mice. High-calci-
um diets containing whey protein prevent weight gain and enhance weight 
loss, α-lactalbumin being the most effective whey protein fraction. Whey 
proteins and calcium have also beneficial effects on hepatic lipid profile 
and adipose tissue gene expression, which suggest a novel mechanistic link 
to explain the epidemiological findings on dairy intake and metabolic syn-
drome. The clinical relevance of these findings and the precise mecha-
nisms of action remain an intriguing field of future research.
12
13introduction
1 introduction
Obesity is a major risk factor for severe chronic disease, such as type 2 
diabetes, metabolic syndrome, other cardiovascular disorders and certain 
types of cancers (for review, see Haslam and James 2005). The worldwide 
prevalence of obesity is increasing both in adults and in children, and the 
significant burden of obesity-related complications is expected to grow. 
Investing resources in the prevention and treatment of obesity are thus 
valuable ways to reduce the overall risk of cardiovascular morbidity and 
mortality.
Nutrition has a crucial role both in the prevention and treatment of 
obesity. Epidemiological studies suggest that milk consumption and a diet 
high in dairy products are one of the few known dietary components which 
are inversely related to body mass index (BMI) (Mirmiran et al. 2005, Mar-
ques-Vidal et al. 2006, Varenna et al. 2007). Epidemiological evidence also 
indicates that the intake of dairy products is related to a lower risk of type 
2 diabetes and metabolic syndrome (Pereira et al. 2002, Liu et al. 2005, 
Liu et al. 2006). Dairy calcium has been suggested to account for the body 
weight-regulating effects of dairy products, and some intervention stud-
ies have indeed shown dairy products and calcium to accelerate weight loss 
during energy restriction (Zemel et al. 2004, Zemel et al. 2005a, Zemel 
et al. 2005b). The results are nevertheless conflicting (Harvey-Berino et 
al. 2005, Thompson et al. 2005, Wagner et al. 2007). Interestingly, both 
clinical and experimental intervention studies indicate that the effect of 
dairy-derived calcium is superior to that of calcium supplementation (Shi 
et al. 2001a, Sun and Zemel 2004a, Zemel et al. 2004).
Dairy proteins, especially whey proteins, have been suggested to play 
a role in the anti-obesity effect of dairy products (for review, see Zemel 
2005). However, the mechanism of action by which dairy products affect 
14
body weight is still unknown. Calcium binds fatty acids in the gastrointes-
tinal tract and thereby decreases the absorption of dietary fat (Jacobsen et 
al. 2005, Lorenzen et al. 2007). Animal and in vitro studies also suggest an 
alternative mechanism whereby dietary calcium may control the adipocyte 
size via 1,25-dihydroxy-vitamin D
3
 (1,25(OH)2D3 ) and the concentration 
of intracellular calcium (for review, see Zemel and Miller 2004, Zemel 
2005). However, the effect of dairy proteins on obesity and the conse-
quent health risks have not been evaluated on a mechanistic level.
The link between obesity and other key elements of the metabolic syn-
drome has been under intensive investigation in recent years. According 
to current understanding, the inflammatory status of adipose tissue is an 
important factor contributing to the overall cardiometabolic risk associ-
ated with obesity (for review, see Hotamisligil 2006). Also the develop-
ment of fatty liver is a crucial phenomenon which links obesity to insulin 
resistance and type 2 diabetes (for review, see Kotronen and Yki-Järvinen 
2007). 
The purpose of the present study was to investigate the potential of 
dairy protein and calcium intake in the prevention and treatment of diet-
induced obesity in C57Bl/6J mice, a well-established model of obesity. 
Another aim was to evaluate the effect of dairy protein and calcium in-
take on the liver and adipose tissue in order to characterise the potential 
mechanisms explaining the reduction of risk for metabolic syndrome and 
type 2 diabetes.
INTRODUCTION
15
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2 review of the literature
2.1 dairy proteins and calcium
Dairy products are a fundamental part of a healthy diet. This is elucidated 
by the current Finnish dietary recommendation, which suggests that dairy 
products should be consumed every day in the form of low-fat liquid dairy 
products, yoghurt or cheese (National Nutrition Council, 2005). Dairy 
products are an essential source of protein, vitamins and minerals and, 
according to FINDIET2002 report, the majority of calcium, phosphorus, 
iodine, riboflavine and vitamin B
12
 intake in the Finnish diet is covered by 
dairy products (Ovaskainen et al. 2003). In addition to proteins, minerals 
and vitamins, milk contains lactose and fat (Fox and McSweeney 1998). 
2.1.1 dairy proteins
On average, bovine milk contains 3.5% of protein (Fox and McSweeney 
1998). The protein is divided into casein and whey fractions which separate 
when the pH of milk is lowered to 4.6. The acidification induces coagula-
tion of casein, whereas whey proteins remain soluble. The relative amount 
of whey proteins and casein in milk varies during lactation and between spe-
cies. On average, the whey to casein ratio in bovine milk is 20:80, whereas 
in human milk the ratio is 60:40. Interestingly, the whey to casein ratio in 
human milk changes during different phases of lactation (Kunz and Lön-
nerdal 1990, 1992). The amount of whey proteins in relation to casein 
decreases from about 90:10 in early lactation to 60:40 in mature milk and 
50:50 in late lactation. In addition, the relative proportion of the differ-
ent casein subunits (Kunz and Lönnerdal 1990) as well as whey proteins 
(Sanchez-Pozo et al. 1986) has been found to vary throughout lactation.
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Since the first report of the American Dairy Science Association Com-
mittee on the Nomenclature, Classification, and Methodology of Milk 
Proteins (Jenness et al. 1956), the classification of dairy proteins has been 
updated every 5 to 10 years (Farrell et al. 2004). The committee reports 
the most significant findings related to nomenclature and methodology of 
dairy proteins and suggests changes in nomenclature where appropriate. 
This shows that the field of dairy proteins is constantly evolving along with 
the technological and methodological development of protein research.
caseins
Caseins are defined as those phosphoproteins that precipitate from raw 
skim milk by acidification to pH 4.6 at 20°C (Farrell et al. 2004). Caseins 
are further divided into different subclasses: α
s1
-, α
s2
-, ß- and k-casein, 
according to the homology of their amino acid sequences. The different 
subclasses represent approximately 37% (α
s1
-), 10% (α
s2
-), 35% (ß-) and 
12% (k-) of total casein (Fox and McSweeney 1998). The caseins are syn-
thesised and secreted by mammary epithelial cells as large aggregates called 
micelles (Bouguyon et al. 2006), which bind minerals, such as calcium, 
inorganic phosphate and magnesium (for review, see Gaucheron 2005). 
Caseins and casein-derived peptides are suggested to have various phys-
iological functions ranging from antibacterial and immunomodulatory 
activities (for review, see Meisel 2005) to their capacity to enhance the 
bioavailability of minerals (for review, see Vegarud et al. 2000, Bouhallab 
and Bougle 2004). Even though most of the suggested properties of ca-
sein-derived peptides are based on experimental and in vitro studies, their 
antihypertensive effect has been demonstrated in clinical studies as well 
(Seppo et al. 2003, Tuomilehto et al. 2004, Jauhiainen et al. 2005).
whey proteins
Whey is the fluid that remains after caseins are removed from milk (for 
review, see Krissansen 2007). Thus, whey contains also minerals, vita-
mins, lactose and traces of fat in addition to proteins. The whey proteins 
are a mixture of different proteins and peptides, some of which are de-
rived from casein during the cheese-making process and end up in whey. 
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Therefore, the composition of total whey protein varies according to the 
manufacturing process and there are several types of whey protein products 
on the market: sweet and acid whey powders, reduced lactose whey, dem-
ineralised whey, whey protein concentrates with different protein contents 
and whey protein isolate, which has the highest protein concentration of 
these products (US Dairy Export Council 2004).
Traditionally, ß-lactoglobulin, α-lactalbumin, serum albumin, im-
munoglobulins, and proteose-peptone fractions have been considered 
the major characterised components of whey proteins (Farrell et al. 2004). 
Whey also contains lactoferrin, lactoperoxidase, insulin-like growth factor 
and other minor proteins (for review, see Yalcin 2006). β-lactoglobulin is 
the major whey protein accounting for approximately half of the total whey 
protein in bovine milk while α-lactalbumin accounts for roughly 25%. 
In vitro studies suggest that whey proteins have various physiological func-
tions from immunomodulatory and anti-inflammatory effects (for review, 
see Krissansen 2007) to anticancer activity (Hakkak et al. 2000, Dave et al. 
2006). The importance of whey proteins has also been under investigation in 
the infant formula industry, since the amount of whey protein is substantially 
greater in human milk than in bovine milk (for review, see Lien 2003).
bioactive peptides
Bioactive peptides are formed from dietary proteins either in the gastroin-
testinal tract during digestion or during the food manufacturing process 
by, for example, fermentation (for review, see Meisel 2005). In the gas-
trointestinal tract, the proteins are subjected to hydrolysis by a variety of 
proteases and peptidases which are either secreted from the stomach and 
pancreas or bound to the brush border membrane of enterocytes (for re-
view, see Daniel 2004). The protein hydrolysis generates a spectrum of 
short- and medium-size peptides, as well as free amino acids. Most pro-
teins and oligopeptides are rapidly degraded. However, the extent and the 
rate by which dietary proteins are broken down are dependent on the pro-
teins' amino acid sequence and post-translational modifications, such as 
glycosylation, which render peptides that are more resistant to hydrolysis. 
Certain whey proteins, such as lactoferrin, have been demonstrated to be 
absorbed intact, at least in mice (Fischer et al. 2007). α-lactalbumin and 
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ß-lactoglobulin are also partly resistant to in vitro digestion with human gas-
tric and duodenal juice (Almaas et al. 2006). Even though a wide range 
of potential health effects of dairy protein-derived peptides are suggested 
by in vitro data (for review, see Meisel 2005, Severin and Wenshui 2005), 
the exact spectrum of peptides formed in vivo after the ingestion of dairy 
products remains unresolved.
2.1.2 calcium
Dairy products account for about two thirds of the calcium intake in the 
Finnish diet (Ovaskainen et al. 2003). Besides the amount of calcium in 
the diet, the absorption is a critical factor in determining the bioavail-
ability of dietary calcium. In milk, the majority of calcium is bound to 
casein micelles, a small proportion is bound to α-lactalbumin and a part 
of the calcium is in the aqueous phase of milk (for review, see Gaucheron 
2005). It has been suggested that certain dairy components, such as casein 
phosphopeptides, may positively influence the absorption of calcium (for 
review, see Bouhallab and Bougle 2004).
Calcium is absorbed in the intestine by two distinct mechanisms (Bron-
ner et al. 1986). An active transcellular mechanism is regulated by 1,25-di-
hydroxyvitamin D (1,25(OH)2D3 ) and is predominant in the duodenum 
and upper jejunum. The 1,25(OH)2D3 is formed in the kidneys from 
25-hydroxyvitamin D by a renal 1α-hydroxylase (for review, see Dusso et 
al. 2005). The synthesis of active vitamin D is regulated by various factors 
including PTH and serum phosphate and calcium levels, but new regula-
tors, such as fibroblast growth factor member 23 and klotho, play a role as 
well (Renkema et al. 2008). The 1,25(OH)2D3 stimulates epithelial calcium 
transport by enhancing calcium entry into the cell, facilitating thus calcium 
movement across the cell and activating the basolateral plasma membrane 
ATPase that pumps calcium from the cell (for review, see Hoenderop et al. 
2000). This active absorption mechanism is predominant when dietary 
calcium intake is low. A passive paracellular absorption process is based on 
concentration-dependent diffusion and takes place throughout the length 
of the intestine especially during high dietary calcium intake.
The importance of calcium intake for bone health is widely recognised 
(Cashman 2002). Sufficient calcium intake is also considered to be an 
α
 
 ß
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important part of the dietary treatment of hypertension (Champagne 
2006). The role of dietary calcium in the regulation of body weight is 
a relatively new area of research. The first observational finding on the 
inverse relationship between calcium intake and body weight in humans 
was published in 1984 (McCarron et al. 1984), and the next report on the 
subject appeared only 8 years ago (Zemel et al. 2000).
2.2 obesity and dairy products
2.2.1 obesity
Obesity is a major risk factor for a number of chronic diseases, includ-
ing diabetes, cardiovascular diseases and cancer (for review, see Haslam 
and James 2005). Obesity is estimated to decrease the life expectancy by 7 
years at the age of 40 years (Peeters et al. 2003) and according to the World 
Health Organisation (WHO), obesity is already responsible for 2–8% 
of health care costs and 10–13% of deaths in different parts of Europe 
(2008). The current estimates suggest that around 2.3 billion adults will 
be overweight and more than 700 million obese by 2015. 
According to WHO, overweight and obesity are defined as abnormal or 
excessive fat accumulation that may impair health (2008). The classifica-
tion of obesity and overweight is commonly based on a simple weight-for-
height index, the body mass index (BMI). BMI is defined as the weight in 
kilograms divided by the square of the height in meters (kg/m2). BMI pro-
vides the most useful population-level measure of overweight and obesity. 
It is the same for both sexes and can be used for all adult age groups. BMI 
correlates well with the amount of fat tissue in the body and also with the 
increased health risks of obesity (Revicki and Israel 1986, Calle et al. 1999). 
WHO divides the definition of obesity into subclasses which correspond to 
the Finnish Current care guidelines (2006). The subclasses are presented 
in Table 1.
22 review of the literature
table 1. definition of obesity according to the finnish current care guidelines (2006) and 
who (2008).
Overweight results from continuous excess energy intake in relation to en-
ergy expenditure (for review, see Flier 2004). Therefore, food and nutri-
tion have a crucial role in the development of obesity. If the energy con-
tent of food is excluded, only few dietary factors have been identified to be 
related to lower BMI. These factors include increased intake of fibre and 
whole grains (for review, see Flight and Clifton 2006), high intake of fruit 
and vegetables (for review, see Tohill et al. 2004) and high intake of dairy 
products (Table 2). On average, dairy products account for 15% (men) to 
16% (women) of daily energy intake in the Finnish diet (Ovaskainen et al. 
2003).
Obesity and particularly abdominal obesity, is a well-established risk 
factor for cardiovascular diseases, type 2 diabetes and metabolic syndrome 
(for review, see Kahn et al. 2006), and the primary goal for obesity treat-
ment is to prevent and treat these chronic diseases. Metabolic syndrome 
is a cluster of cardiovascular risk factors including abdominal obesity, el-
evated plasma glucose, dyslipidemia, hypertension and prothrombotic/
proinflammatory state (Grundy 2008). Depending on the diagnostic cri-
teria, at worst, every fifth middle-aged man and every sixth woman in Fin-
land can be diagnosed as having metabolic syndrome (Hu et al. 2004). At 
present, patients with metabolic syndrome are often treated with multiple 
drugs. Multiple drugs are needed to target the different comorbidities of 
metabolic syndrome, because none of the approved drugs on the mar-
ket can reliably reduce all of the metabolic risk factors in the long term 
 classification bmi (kg/m2)
current care guidelines who definition 
normal range 18.50 - 24.99
overweight  ≥ 25.00
slightly obese pre-obese 25.00 - 29.99
obese  ≥ 30.00
significantly obese obese class i 30.00 - 34-99
severely obese obese class ii 35.00 - 39.99
morbidly obese obese class iii ≥ 40.00
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(Grundy 2006). Thus, there is growing interest in therapeutic strategies 
that might target multiple factors more efficiently, thereby minimising the 
problems of polypharmacy. Life-style therapies are currently the recom-
mended first-line treatment for metabolic syndrome and the nutritional 
approaches are especially crucial in the preventive management of this 
growing epidemic.
2.2.2  obesity and the intake of dairy products:  
 epidemiological studies 
The intake of dairy products correlates negatively with BMI or body weight 
in several, but not all, of the studied populations (Table 1). The largest 
(n=37 513) of the population studies is based on the Portuguese National 
Health Interview survey (Marques-Vidal et al. 2006) which showed that 
BMI increased with decreased milk intake. In addition to the Portuguese 
population, the inverse association of dairy product intake and body weight 
has been demonstrated in Italian postmenopausal women (Varenna et al. 
2007) and in Canadian (Drapeau et al. 2004) and Iranian adults (Mirmi-
ran et al. 2005, Azadbakht and Esmaillzadeh 2007). No relationship was 
detected in a Japanese study on 1 905 female dietetic students (Murakami et 
al. 2006). The subjects in that study were within a very narrow BMI range, 
78% having BMI of 18.5 to 24.9 kg/m2 and only 6% having BMI ≥ 25 kg/
m2. Also the intake of dairy products was low even in the highest quartile of 
dairy intake, where it was comparable with the lowest quartile of US (Ra-
jpathak et al. 2006) or European studies (Snijder et al. 2007). 
Interestingly, some of the studies have found an inverse association 
between BMI and high-, but not low-fat, dairy products (Rajpathak et al. 
2006, Rosell et al. 2006, Snijder et al. 2007). Unfortunately, the type of 
dairy product has not been reported in all of the studies. This is a critical 
confounding factor which is likely to explain the inconsistency between 
different studies. In addition to the dairy product type, the assortment 
and the traditional use of dairy products vary greatly between different 
populations. For example, the intake of chocolate milk and non-flavoured 
milk were treated as comparable in the analysis of a longitudinal study of 9- 
to 14-year-old adolescents (Berkey et al. 2005) and in the Bogalusa Heart 
Study (Brooks et al. 2006). An estimate of dairy intake from foods, such 
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as pizza, nachos, lasagne and puddings, was also included in the analysis 
of the Bogalusa Heart Study. On the other hand, some studies have only 
recorded the fluid milk intake (Marques-Vidal et al. 2006) which compli-
cates the comparison of the epidemiological data.
A recent review of dietary patterns and the risk of metabolic syndrome 
concluded that even though there is some inconsistency in the literature 
regarding the risk of obesity, high dairy intake is generally associated with 
a reduced risk for components of the metabolic syndrome (Baxter et al. 
2006). Indeed, the epidemiological data on dairy product intake and the 
risk of metabolic syndrome are more consistent along with the data on 
high dairy intake and lower risk of type 2 diabetes (Table 2).
Taken together, there is growing line of epidemiological evi-
dence of the protective effect of dairy product intake against 
overweight and obesity. The inverse relationship has been 
demonstrated in different countries and age groups as well as 
in both sexes. In addition to obesity, dairy product intake is 
associated with a reduced risk of metabolic syndrome and type 
2 diabetes in several epidemiological datasets. 
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2.2.3  obesity and the intake of dairy products:  
 randomised clinical trials
weight loss
Most of the randomised clinical trials designed to investigate the effect of 
dairy product intake on body weight have been weight loss trials. Intake of 
dairy products has been found to significantly increase weight loss dur-
ing energy restriction (Zemel et al. 2004, Zemel et al. 2005a, Zemel et al. 
2005b). In these 12- to 24-week trials, a 500 kcal daily energy restric-
tion has been combined with either low (0-1 portions) or high (3 por-
tions) intake of dairy products. High dairy intake has resulted in 1.5 to 
2.3-fold greater body weight loss than low dairy intake. However, despite 
comparable study designs, a similar effect has not been found in all of the 
studies (Harvey-Berino et al. 2005, Thompson et al. 2005). Wagner and 
co-workers (2007) studied the differences between placebo and calci-
um lactate, calcium phosphate and low-fat milk supplementation during 
weight loss, but none of the calcium supplementations or milk increased 
weight or fat loss in comparison with placebo. This is in contrast with the 
study by Zemel et al. (Zemel et al. 2004), which demonstrated that the 
effect of dairy calcium was significantly greater than the effect of supple-
mental calcium.
One of the factors differentiating the clinical trials is the BMI of the 
study subjects. All of the studies which support the effect of dairy in weight 
loss have been conducted with obese subjects (BMI>30), whereas studies 
by Wagner (2007) and Harvey-Berino et al. (2005) included overweight 
subjects (BMI 25–30) as well. Also Bowen and colleagues (2005) studied 
subjects with BMI 25 or above. They could not detect any difference dur-
ing a 12-week weight loss trial on two high-protein diets; one with high 
dairy protein and high calcium and the other with mixed protein and low 
calcium. 
The effect of dairy products on body weight has also been reported 
in intervention trials, which have not been primarily designed to study 
the association of dairy intake and body weight. Data from a randomised 
6-month clinical trial assessing the effect of three isocaloric diets in type 2 
diabetic patients showed an association of dairy calcium intake with weight 
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loss (Shahar et al. 2007). Besides weight, serum triglyceride levels were sig-
nificantly improved in line with the consumption of dairy calcium.
weight gain
A few studies have addressed the issue of weight gain or alteration of body 
composition as a consequence of increased dairy calcium intake, but the 
results are contradictory (Gunther et al. 2005a, Zemel et al. 2005b, Eagan 
et al. 2006). A 24-week increased dairy calcium intake on isocaloric diet 
significantly decreased the fat mass of obese African-American subjects 
(Zemel et al. 2005b) but did not have an effect on body weight or fat 
mass in healthy young women during a 1-year follow up (Gunther et al. 
2005a). The African-American subjects also had significantly improved 
insulin and blood pressure values as a result of increased dairy calcium 
intake and subsequent decrease in fat mass. Eagan and colleagues contin-
ued the study of Gunther et al. and analysed the fat mass of the subjects 
six months after the end of the trial (Eagan et al. 2006). They found 
that the subjects had maintained the level of dairy calcium intake after 
the trial and that the calcium intake over 18 months predicted a negative 
change in body fat mass.
Taken together, the randomised clinical trials aiming at in-
vestigating the effect of dairy products or dairy calcium on 
body weight are not totally conclusive. Most of the studies which 
have investigated the effect of dairy products on weight loss in 
obese subjects support the hypothesis that dairy products aug-
ment the effect of weight loss. The effect of dairy products on 
weight gain or modification of body composition is less clear 
and more studies are needed in that area.
2.2.4  obesity and the intake of dairy products:  
 experimental studies
Experimental studies investigating the effect of dairy on body weight have 
mainly concentrated on the effect of calcium and body weight instead of 
the effect of dairy products. Zemel and co-workers have successfully in-
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cluded also dairy-based high-calcium diets in their studies and the results 
repeatedly demonstrate that calcium in combination with dairy is more 
effective than supplemental calcium alone. The results from animal mod-
els support the role of calcium in inhibiting body weight gain in male rats 
(Papakonstantinou et al. 2003) and mice (Zemel et al. 2000, Sun and Zem-
el 2006, Parra et al. 2007). A high-calcium diet also increased weight loss 
in two different mouse models (Shi et al. 2001a, Sun and Zemel 2004a, 
Parra et al. 2007) and attenuated weight regain after weight loss (Sun and 
Zemel 2004a).
However, the experimental evidence does not support the role of calci-
um deficiency in the development of obesity (Paradis and Cabanac 2005). 
Also the effect of calcium on body weight in high- or normal-fat diet-fed 
female C57Bl/6J mice and Sprague Dawley rats is questionable (Zhang and 
Tordoff 2004).
In addition to the effects on body weight, high-calcium diet has been 
shown to decrease the expression of pro-inflammatory factors tumour 
necrosis factor-alpha and interleukin-6 and to stimulate the expression of 
the anti-inflammatory factors interleukin-15 and adiponectin in mouse 
visceral fat (Sun and Zemel 2007b). An increased expression of inter-
leukin-15 was also observed in the soleus muscle of these mice in com-
parison with control mice on a low-calcium diet. The high-calcium diet 
has also been shown to reduce the production of reactive oxygen species in 
visceral and subcutaneous adipose tissue in mice (Sun and Zemel 2006). 
Adipose tissue inflammation and oxidative stress are considered to con-
tribute to the development of insulin resistance and metabolic syndrome 
(Hotamisligil 2006). Hence, these preliminary findings suggest that di-
etary calcium not only modulates body weight but has beneficial effects on 
the overall cardiometabolic risk of obesity. In addition, studies in the dia-
betic rat model suggest that a fermented dairy product, Dahi, alleviates the 
development of type 2 diabetes (Yadav et al. 2006a, 2006b, 2007). Addi-
tionally, a whey protein-containing high-protein diet has been shown to 
increase insulin sensitivity and lower weight gain in comparison with red 
meat-fed control animals (Belobrajdic et al. 2004). These results suggest 
that not only calcium but also other dairy components may affect the risk 
of obesity-related co-morbidities.
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To sum up, the experimental evidence on the effect of dairy 
products on body weight is fairly conclusive, but the results are 
based on a limited number of studies and an even more lim-
ited number of different animal models. The preliminary ev-
idence suggests that calcium and other dairy components may 
play a role in the prevention of obesity-related co-morbidities, 
such as type 2 diabetes. However, there is an undisputed need 
for experimental studies designed for clarifying the role and 
mechanisms of dairy components in the prevention and treat-
ment of obesity and metabolic syndrome.
2.3 obesity and dairy components 
the idea that dairy foods have a role in the regulation of body weight was 
first set out when McCarron and colleagues (1984) studied the relation-
ship between the intake of dietary minerals and hypertension. As a sec-
ondary finding they observed that calcium intake was inversely related to 
body mass index. Since dairy is the major dietary source of calcium, the 
role of dairy was subsequently assessed. Based on this history, calcium is 
by far the most studied dairy component in the field of obesity, whereas 
studies on the contribution of the other nutritional components of dairy 
are limited.
2.3.1 calcium
The relationship of calcium intake and body weight has been investigated 
in several epidemiological studies (Table 4). Since dairy products are the 
major dietary source of calcium, the role of dairy in these studies cannot 
be ruled out. On the whole, epidemiological data on the relationship of 
calcium intake and obesity are based on smaller population samples than 
the data on dairy consumption and obesity (Table 2). The studies on chil-
dren and adolescents are more inconclusive than the studies on adults. In 
accordance with the epidemiological data on dairy intake and markers of 
metabolic syndrome, the epidemiological data support the inverse associa-
tion between calcium intake and central adiposity, glucose disorders and 
serum lipid profile.
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The effect of dietary calcium on body weight has recently been evaluated 
in a review by Lanou and Barnard (2008) and in a meta-analysis by Trow-
man et al. (2006). After evaluating 48 (Lanou and Barnard 2008) and 
13 (Trowman et al. 2006) randomised controlled trials using calcium sup-
plementation and/or dairy products as an intervention, the authors con-
cluded that calcium supplementation has no significant association with 
a reduction in body weight. However, only one of the studies reviewed by 
Trowman et al. (Zemel et al. 2004) was specifically designed and powered 
to examine whether calcium supplementation affects body weight while the 
other studies were designed to investigate bone mass during calcium treat-
ment. Of the 48 trials evaluated by Lanou and Barnard, only five stud-
ies (Lappe et al. 2004, Reid et al. 2005, Zemel et al. 2005b, Lorenzen et 
al. 2006, Caan et al. 2007) were designed to investigate the effect of cal-
cium/dairy supplementation on weight gain, whereas eight were designed 
to investigate the effect of calcium/dairy supplementation on weight loss 
(Shapses et al. 2004, Zemel et al. 2004, Bowen et al. 2005, Harvey-Berino 
et al. 2005, Thompson et al. 2005, Zemel et al. 2005a, Zemel et al. 2005b, 
Major et al. 2007). Most of the remaining studies included in the above 
review were designed to study the effect of calcium supplementation on 
bone-related outcomes. 
Of the studies specifically designed and powered to investigate the ef-
fect of calcium supplementation on body weight, only three studies on 
weight gain and two on weight loss were conducted using calcium supple-
ments. Calcium supplementation did not enhance weight loss in either of 
the weight loss trials (Shapses et al. 2004, Major et al. 2007) and weight gain 
was inhibited in only one of the three trials (Caan et al. 2007). Keeping 
in mind that dairy supplementation has been shown to affect body weight 
in several trials (Zemel et al. 2004, Zemel et al. 2005a, Zemel et al. 2005b, 
Eagan et al. 2006), it can be argued that the effect of dairy is superior to 
that of calcium supplementation, as has been shown in an intervention 
study (Zemel et al. 2004).
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2.3.2 dairy proteins
In vitro studies suggest that dairy proteins have various physiological func-
tions (Yalcin 2006). Dairy proteins are also a source of various bioactive 
peptides with for example ACE-inhibitory properties, opioid-like activi-
ties and mineral-binding and antithrombotic properties (for review, see 
Jauhiainen and Korpela 2007). Thus the hypothesis that dairy protein-
derived peptides might modulate also energy metabolism-related pathways 
is plausible, but studies on the area are scarce.
Many of the currently known dairy-derived peptides with ACE-inhib-
itory properties, such as Ile-Pro-Pro and Val-Pro-Pro, are derived from 
casein (Jauhiainen and Korpela 2007). The local renin-angiotensin-
aldosterone system in adipose tissue is postulated to play a role in the 
development of type 2 diabetes and metabolic syndrome but the molec-
ular mechanisms are not yet fully understood (Sharma 2006). Hence, 
milk-derived ACE-inhibitory peptides may in theory contribute to the 
decreased risk of metabolic syndrome and type 2 diabetes in high dairy 
consumers.
Whey has been reported to inhibit body weight gain in Wistar rats in 
comparison with red meat (Belobrajdic et al. 2004) and casein (Royle et 
al. 2007). A whey protein-rich diet has also been shown to have an influ-
ence on liver and muscle lipogenic enzyme activities in rats (Morifuji et al. 
2005a, Morifuji et al. 2005b). Whey proteins may also have satiety- in-
creasing properties (Luhovyy et al. 2007), which may influence obesity.
In addition to various bioactive protein components, the amount of 
branched-chain amino acids; leucine, isoleucine and valine, is high in total 
whey protein. Leucine, in particular, is known to have various metabolic 
functions including the initiation of muscle protein synthesis (Anthony et 
al. 2001) and modulation of the insulin/PI3 -kinase signalling (Patti et al. 
1998), and long-term leucine supplementation has been shown to increase 
body fat loss during food restriction in Wistar rats (Donato et al. 2006).
2.3.3 other dairy components
With regard to calcium intake, dairy products represent the major die-
tary source, which is not the case with other minerals or vitamins in dairy 
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(Ovaskainen et al. 2003). Hence, the inverse relationship between dairy 
intake and body weight is unlikely to be explained by other minerals or 
vitamins. 
The intake of dairy fat has been traditionally linked to an increased risk 
of cardiovascular disease. This is mainly due to the high amount of saturated 
fatty acids which have unfavourable effects on serum lipids (Matthan et al. 
2004), (Tholstrup et al. 2004). Interestingly, a Swedish longitudinal study 
found the increased intake of whole milk and cheese, in particular, to be 
inversely associated with weight gain during a 9-year follow-up (Rosell et al. 
2006). A similar association was found in two other epidemiological studies 
as well (Rajpathak et al. 2006, Snijder et al. 2007). In addition, cheese con-
sumption was associated with a more favourable cardiovascular risk profile 
in a recent publication (Houston et al. 2008). Most of the epidemiological 
studies do not distinguish between the types of dairy products and hence the 
contribution of high-fat versus low-fat dairy products to the risk of obesity 
and metabolic disorders is difficult to comprehend. However, a possibility 
of dairy containing bioactive lipid components that contribute to the regu-
lation of body weight and cardiometabolic risk, cannot be ruled out.
One lipid component of dairy, which has been suggested to have fa-
vourable effects on body weight, is conjugated linoleic acid (CLA) (for 
review, see Silveira et al. 2007). Despite numerous studies on CLA’s effects 
on body composition for nearly a decade, the mechanisms by which CLA 
isomers elicit their effects remain largely unknown. Intervention studies 
suggest that the potentially effective form of CLA is in particular the trans-
10,cis-12 isomer (for review, see Wang and Jones 2004), whereas CLA 
in dairy products is mainly in the form of the cis-9,trans-11 isomer. Ad-
ditionally, some studies raise concern about the possibility of deleterious 
effects of trans-10,cis-12 CLA on lipid profile, glucose metabolism and 
insulin sensitivity. The dietary intake of CLA has been estimated to be 
around 200 mg/day in US adults, dairy products accounting for approxi-
mately 90% of the intake (Ritzenthaler et al. 2001). However, the amount 
of CLA in the intervention studies has been 3.5 to 34-fold in comparison 
with the average intake (for review, see Silveira et al. 2007). Therefore, it is 
not likely that the potential body weight-regulating effects of dairy would 
be explained by CLA.
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To sum up, the epidemiological data do support the role of cal-
cium in reducing obesity-related co-morbidities, such as in-
sulin resistance, but the data on BMI are more inconclusive, 
especially in children and adolescents. Randomised clinical 
studies designed and powered to study changes in body weight 
suggest that calcium supplementation is not as effective as dairy 
in regulating body weight. Scattered experimental evidence sup-
port the multiple health benefits of dairy proteins and dairy 
protein-derived peptides. The beneficial amino acid composi-
tion also supports the potential health effects of dairy proteins.
2.4 possible mechanisms of action
2.4.1 calcium and fat absorption
One of the mechanisms by which calcium may modulate body weight is 
by binding fatty and bile acids in the gastrointestinal tract (Van der Meer 
et al. 1990, Denke et al. 1993, Welberg et al. 1994, Papakonstantinou et al. 
2003, Jacobsen et al. 2005). Calcium forms insoluble fat-calcium soaps 
in the intestine and thereby increases fat excretion. In humans, the in-
creased fat excretion has only been measured in short-term studies, and 
the potential effect of this increased fat excretion on body weight has been 
estimated without taking into account the actual fat intake during/prior 
to the collection of faeces. Depending on the study, the fat excretion has 
increased from 1.6 (Boon et al. 2007b) to 2.5-fold (Jacobsen et al. 2005) 
on a high-calcium diet in comparison with a low-calcium diet. It has been 
argued that even though the effect of calcium on fat excretion is significant 
in certain clinical settings, it is too small to explain the effects on body 
weight (Zemel 2005, Major et al. 2008). Indeed, the only study which has 
demonstrated that increased fat excretion in the high-calcium fed group 
accounted for a substantial amount of body weight decrease was a study in 
rats, in which the apparent fat absorption was calculated from fat intake 
and fat excretion data (Papakonstantinou et al. 2003). 
In order for calcium to bind dietary fatty acids, it should be present 
in the gastrointestinal tract at the same time with the dietary fat. In this 
regard, dairy products have a clear advantage, since they are more likely 
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to be ingested simultaneously with dietary fat than supplemental calcium. 
However, even when ingested simultaneously with a meal, supplemental 
calcium has a smaller effect on postprandial lipid absorption than dairy 
calcium (Lorenzen et al. 2007). The reason for this is currently not under-
stood, but the differences in the chemical form of calcium or yet unknown 
cofactors in dairy products have been suggested to play a role in this.
To summarise, dietary calcium increases the faecal fat excre-
tion in both humans and animals by formation of insoluble 
fat-calcium soaps. This mechanism presumes calcium and fat-
ty acids to be present in the intestine at the same time, whereby 
dairy calcium has a clear advantage against supplemental calci-
um, since it is more likely provided with the meal. Preliminary 
evidence suggests that dairy calcium also suppresses postpran-
dial lipid absorption significantly more than supplemental 
calcium, but the mechanisms explaining the phenomena are 
unclear. Most of the clinical evidence on calcium’s effect on 
faecal fat excretion is based on acute studies and hence the 
long-term effects on body weight need further studies.
2.4.2  calcium, 1,25(oh)2-vitamin d3 and 
 intracellular calcium
One of the key regulators of calcium homeostasis in the body is 
1,25(OH)2D3  (for review, see Dusso et al. 2005). During low dietary cal-
cium intake, the level of 1,25(OH)2D3  increases, which in turn stimulates 
the absorption of calcium in the small intestine. Since dietary calcium 
intake is one of the regulators of serum 1,25(OH)2D3 levels, it has been 
hypothesised that the effect of calcium on body weight would also be in-
duced via 1,25 (OH)2D3.
The actions of 1,25(OH)2D3 in the adipocytes are in part mediated via 
intracellular calcium (Figure 1). A high level of 1,25(OH)2D3 increases in-
tracellular calcium concentration in isolated human adipocytes by stimu-
lating the influx of calcium into the adipocytes (Zemel et al. 2000, Shi et 
al. 2001b). The high concentration of intracellular calcium subsequently 
increases lipogenesis through increased fatty acid synthase expression and 
?? ????????????????????????
???????????????????????????????????????????????????????????????????????????????
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studies do not support the theory that increased calcium intake or changes 
in 1,25(OH)2D3 would affect fatty acid synthase expression (Boon et al. 
2005a, Boon et al. 2006, Boon et al. 2007b), but there is preliminary 
evidence supporting the effect of intracellular calcium modification on 
lipolysis (Boon et al. 2007a).
The studies on cultured adipocytes suggest additional mechanisms by 
which 1,25(OH)2D3 may mediate the effects of dietary calcium. These ac-
tions include inhibition of the uncoupling protein 2 expression through 
nuclear vitamin D receptors and subsequent regulation of thermogene-
sis (Shi et al. 2002) and attenuation of adipocyte apoptosis through un-
coupling protein 2 inhibition (Sun and Zemel 2004b). On the other 
hand, 1,25(OH)2D3 has been shown to inhibit adipocyte differentiation 
(Kong and Li 2006) and therefore decreasing PTH and subsequently 
1,25(OH)2D3 by dietary calcium would lead to increased adipogenesis. It 
should be noted that activation of vitamin D receptor mediates the expres-
sion of numerous genes. For example, nearly 200 genes in human smooth 
muscle cells were affected as a result of vitamin D receptor activation (Wu-
Wong et al. 2007). Therefore, the hypothesis by Zemel et al. may be an 
oversimplified representation of the situation. Furthermore, the epide-
miological studies on the relationship between serum 1,25(OH)2D3 levels 
and obesity are conflicting as well (Bell et al. 1985, Zamboni et al. 1988, 
Parikh et al. 2004).
In addition to obesity, 1,25(OH)2D3 may be associated with obesity-
related comorbidities. Preliminary findings from cell culture studies and 
aP2 transgenic mice suggest that 1,25(OH)2D3  promotes inflammatory 
cytokine expression, inhibits anti-inflammatory cytokine expression (Sun 
and Zemel 2007b) and modulates formation of reactive oxygen species 
(ROS) via uncoupling protein 2 and intracellular calcium (Sun and Zemel 
2006, 2007a). Hence, decreasing the level of 1,25(OH)2D3  by dietary cal-
cium would decrease the inflammatory cytokine production and ROS for-
mation in the adipose tissue and consequently contribute to the decreased 
risk of metabolic syndrome and type 2 diabetes. However, 1,25(OH)2D3 
has also been shown to protect against oxidative stress (Bao et al. 2008) and 
to have anti-inflammatory properties (Zittermann et al. 2005, Giulietti et 
al. 2007). It is therefore obvious that the role of 1,25(OH)2D3 is not yet 
clear in the modulation of inflammatory and oxidative stress.
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Taken together, 1,25(OH)2D3 offers an intriguing mecha-
nistic explanation for the effects of dietary calcium. There is 
accumulating evidence on the role of 1,25(OH)2D3 in adi-
pose tissue metabolism, but the results are mainly based on in 
vitro data and are yet inconclusive. The theory on the effects 
of 1,25(OH)2D3 on adipose tissue is partly connected to adi-
pocyte intracellular calcium levels. However, the significance 
of adipocyte intracellular calcium as a regulator of adipocyte 
size and metabolism is supported by a limited amount of ex-
perimental data and their relevance remains to be elucidated. 
In addition, the epidemiological and clinical evidence on the 
role of 1,25(OH)2D3  in obesity warrants further research.
2.4.3 calcium and fat oxidation
The effects of increased calcium and dairy product intake on body weight 
have also been explained by increased fat oxidation. Fat oxidation has 
been studied after either short-term (Melanson et al. 2003, Gunther et 
al. 2005b, Cummings et al. 2006) or chronic calcium intake (Boon et al. 
2005a, Gunther et al. 2005b, Jacobsen et al. 2005, Melanson et al. 2005, 
Teegarden et al. 2008) and the results from both settings are inconclusive. 
Interestingly, some studies have found a difference in the effect between 
dairy and supplemental calcium (Teegarden et al. 2008) while others have 
not (Melanson et al. 2003, Cummings et al. 2006). Most of the studies 
have investigated the effect of calcium on fat oxidation during isocaloric 
conditions, but also acute (Melanson et al. 2005) and long term energy re-
striction (Teegarden et al. 2008) approaches have been used. Both energy 
restriction studies support the hypothesis that calcium intake increases fat 
oxidation. However, only supplemental, but not dairy, calcium was found 
to increase fat oxidation after a long-term (12-week) calorie restriction 
(Teegarden et al. 2008). 
One possible mechanism by which dietary calcium could increase fat 
oxidation is via 1,25(OH)2D3 and uncoupling protein 2 (Shi et al. 2002). 
The 1,25(OH)2D3 inhibits uncoupling protein 2 expression via nuclear 
vitamin D receptor in human adipocytes in vitro and hence suppressing 
1,25(OH)2D3 levels through increased dietary calcium intake may increase 
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uncoupling protein 2 expression and subsequently fat oxidation. Actions 
mediated by serum PTH levels have also been suggested (Teegarden et al. 
2008).
2.4.4 dairy proteins and satiety
The role of satiety-related signals and pathways in the regulation of body 
weight has been an area of intensive research in the past years. Increased 
intake of dietary protein is known to increase satiety and decrease food in-
take more than the intake of fat or carbohydrates (Porrini et al. 1997, Lat-
ner and Schwartz 1999, Lejeune et al. 2006), resulting in both improved 
weight loss and weight loss maintenance (Skov et al. 1999, Dumesnil et al. 
2001, Westerterp-Plantenga et al. 2004, Lejeune et al. 2005). However, it 
is still not fully understood how increased protein intake increases satiety 
and hence also the role of different proteins in satiety-mediated weight 
management remains unclear. Since dairy products are an important 
source of dietary protein (Ovaskainen et al. 2003), their effect on body 
weight may be related to their satiety-inducing properties.
Whey has been demonstrated to have greater satiety effect than casein 
(Hall et al. 2003), soy or egg albumin (Anderson et al. 2004) in some but 
not all of the studies (Bowen et al. 2006a, Bowen et al. 2006b). The diges-
tion of whey and absorption of its amino acids is faster than that of casein, 
whereby these proteins are classified as "fast" and "slow" protein, respec-
tively (Boirie et al. 1997, Dangin et al. 2002). In humans, the intake of whey 
results in fast, but short and transient increase in plasma amino acids. In 
contrast, casein results in a slower and lower rise in plasma amino acid con-
centrations but sustains a prolonged plateau after consumption. Therefore, 
it has been suggested that milk-induced satiation and satiety are a result 
of synergistic action of whey proteins providing early and casein providing 
overlapping but later signals (for review, see Luhovyy et al. 2007). 
In the controlled clinical trials which have investigated the effects of 
dairy intake on body weight, the average energy or protein intake has not 
differed between the high and low dairy groups (Zemel et al. 2004, Zemel 
et al. 2005a, Zemel et al. 2005b). Accordingly, at least in these studies, the 
potential satiety effect of dairy proteins is not likely to play a role. The same 
can be concluded from the experimental studies studying dairy protein-
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based diets (Zemel et al. 2000, Shi et al. 2001a, Sun and Zemel 2004a). 
In the epidemiological studies reporting the inverse relationship between 
BMI or body weight and dairy intake, the correction for protein intake has 
not been widely used. Therefore, it is possible that the satiety effect of dairy 
proteins plays a role in the regulation of body weight in the long run.
To summarise, diets high in protein are considered to increase 
satiety and support weight management. Dairy products are an 
important source of dietary protein and dairy proteins may have 
a greater satiety effect than other protein sources. Therefore, 
the satiety effect of dairy proteins may play a role in the epide-
miological findings on dairy intake and body weight, but this 
has not been studied. The subjective satiety or levels of satiety 
hormones have not been studied during the experimental and 
clinical interventions which have focused on the effect of dairy 
product intake on body weight. However, energy and protein in-
takes have not differed between the intervention groups in these 
studies and hence the results cannot be explained by a decreased 
energy intake which would have resulted from greater satiety.
2.4.5 dairy proteins and insulin action
Insulin resistance is a central element of obesity, metabolic syndrome and 
type 2 diabetes, and recent data demonstrate that chronic, low-grade in-
flammation associated with obesity is an important mechanism decreas-
ing insulin signalling (for review, see de Luca and Olefsky 2008). Dairy 
products increase the postprandial insulin response, which is reduced in 
type 2 diabetic subjects (Liljeberg Elmståhl and Björck 2001, Östman et al. 
2001). Whey protein, in particular, has been demonstrated to contrib-
ute to better glycaemic control due to its greater post-prandial insulino-
trophic effect as compared with casein (Nilsson et al. 2004, Frid et al. 2005, 
Tessari et al. 2007). 
The insulinotrophic effect of whey protein is likely to be mediated 
through several mechanisms. The rapid amino acid absorption and the 
substantial amount of certain insulinotrophic amino acids (isoleucine, 
leucine, lysine, threonine, valine) result in great post-prandial insuline-
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mic response (Nilsson et al. 2007). Whey proteins also increase the con-
centration of incretin hormones by inhibiting the activity of dipeptidyl 
peptidase IV, the enzyme that catalyses the inactivation of the incretin 
hormones in the gastrointestinal tract (Gunnarsson et al. 2006). Incretin-
based therapies, including glucagon-like peptide 1 analogues and dipepti-
dyl peptidase IV inhibitors, have been shown to restore glucose homeostasis 
and improve glycaemic control and are thus considered a promising new 
treatment option for patients with type 2 diabetes (for review, see Drucker 
and Nauck 2006, for review, see Pratley and Salsali 2007). The recent 
meta-analysis of incretin therapies also concluded that treatment with 
dipeptidyl peptidase IV inhibitors resulted in some improvements in trig-
lycerides and low- and high-density lipoprotein cholesterol levels (Amori 
et al. 2007). The postprandial insulinotrophic effect of dairy, combined 
with the possible dipeptidyl peptidase IV inhibitory activity of whey, may 
thus in theory contribute to the decreased risk of metabolic syndrome and 
type 2 diabetes in high dairy consumers.
Taken together, dairy products and especially whey protein may 
favourably affect the postprandial glycaemic control. However, 
the current data only support the acute postprandial increase 
of insulin response. Furthermore, it has not been established 
whether long term consumption of diet high in dairy products 
has a stable effect on glycaemic control.
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3 aims of the study
Consumption of a diet high in dairy products is associated with lower 
BMI, reduced risk of type 2 diabetes and lower incidence of metabolic 
syndrome. Earlier studies have shown that dietary calcium modifies body 
weight and adipose tissue metabolism and that the effect of calcium from 
dairy sources is superior to the effect of supplemental calcium. Dairy pro-
teins have been suggested to play a role in the modulation of body weight, 
but the effects of dairy proteins in combination with calcium at differ-
ent stages of obesity are not well understood. Furthermore, the effect of 
calcium and dairy proteins on adipose tissue and liver metabolism, which 
play a central role in the development of metabolic syndrome and type 2 
diabetes, is not known. The present study investigated these effects of cal-
cium and dairy proteins in more detail by using a well established animal 
model of diet-induced obesity.
The specific aims of the study were: 
1.  To evaluate the potential of dairy protein and calcium intake in the 
  prevention and treatment of diet-induced obesity (I, II, III, IV).
2.  To study the effect of dairy protein and calcium intake on adipose tissue 
  and the liver in order to characterise the potential mechanisms ex- 
 plaining the reduction of risk for metabolic syndrome and type 2 dia- 
 betes (III, IV).
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4 materials and methods
4.1 study design
All of the studies were conducted with male C57Bl/6J mice. The C57Bl/6J 
mouse is a well-established model of diet-induced obesity (Surwit et al. 
1988, Collins et al. 2004, Koza et al. 2006). This inbred mouse strain 
develops obesity and insulin resistance when fed a high-fat diet and thus 
serves as a human-like experimental model of obesity research.
The studies evaluated the effect of dairy proteins and calcium at differ-
ent phases of obesity. Study I concentrated on the prevention of weight 
gain (Figure 2), whereas Study II investigated the effect of dairy proteins 
and calcium on weight loss and subsequent weight re-gain. Study III evalu-
ated the changes in adipose tissue gene expression as a result of weight 
gain and Study IV concentrated on the hepatic effect of dairy proteins and 
calcium during weight loss.
Figure 2. The illustrative body weight curve describing the different phas-
es of body weight studied in this thesis. 
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4.2 materials
4.2.1 experimental animals
All of the studies were carried out on 8-week-old male C57Bl/6J mice, 
which were purchased from Harlan (Horst, The Netherlands). The mice 
were housed five in a cage in a standard experimental animal laborato-
ry, illuminated from 6.30 a.m. to 6.30 p.m., temperature 22±1°C. The 
protocols were approved by the Animal Experimentation Committee of 
the University of Helsinki, Finland, permission number HY 22-05. The 
mice had free access to feed and tap water during the experiments. After 
a 1-week acclimatisation period on a normal chow diet (Harlan Tekland 
2018, Harlan Holding, Inc., Wilmington, DE, USA), the mice were put 
on a high-fat diet for 21 (Studies I, III and IV) or 28 weeks (Study II).
In Studies I and III, the body weight-matched mice were divided into 
treatment groups in the beginning of the high-fat feeding (weight gain) 
phase (Figure 2). In Studies II and IV, the body weight-matched mice were 
divided into treatment groups after 14-week ad libitum feeding on a high-fat 
diet and subjected to energy restriction for 7 weeks (weight loss phase). 
During the energy restriction period, the energy intake of the mice was 
limited to 70% of the energy intake of the ad libitum feeding. In Study II, 
part of the mice were sacrificed after the weight loss phase and the remain-
ing mice were fed ad libitum for another 7 weeks (weight re-gain phase).
4.2.2 diets and groups
All of the high-fat diets were manufactured by Research Diets Inc. (New 
Brunswick, NJ, USA). The diets were based on the standard DIO-diet 
containing 60% of energy in fat (D12492). In the study diets, the amount 
of calcium and the source of protein were modified according to the study 
design. The specifications of the diets are presented in Table 5. The lean 
control group in Study IV was fed a regular rodent chow (Harlan Tek-
lad 2018, Harlan Holding, Inc., Wilmington, DE, USA) instead of a 
high-fat diet. The powdered diets were moistened with tap water (200 ml/
kg in whey and beta-lactoglobulin, 205 ml/kg in alpha-lactalbumin, 190 
ml/kg in lactoferrin, 100 ml/kg in casein and 110 ml/kg in control and 
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700 ml/kg in the normal chow diet) using an industrial dough mixer and 
packed in one-day portions and stored at -20ºC.
The labelling of the groups varies in the original publications. In this 
thesis, the groups are named as follows:
table 5. diets and labelling of the groups used in this thesis.
iv
  name of 
the group
diet characteristics 
(fat, ca, protein)
diet reference 
(producer)   study   
control high-fat (60% of energy), 
low-ca (0.4%), casein 
(18% of energy)
 d05031101m 
(research diets inc.)
i, ii, iii, iv   
high-ca whey high-fat (60% of energy), 
high-ca (1.8%), whey (18% of 
energy)
d05031104m 
(research diets inc.)
i, ii, iii, iv   
high-ca high-fat (60% of energy), 
high-ca (1.8%), casein (18% of 
energy)
d05031102m (research 
diets inc.)
i, 
unpublished   
whey high-fat (60% of energy), 
low-ca (0.4%), whey 
(18% of energy)
d06050901m  
(research diets inc.) 
unpublished  
α-lactalbumin high-fat (60% of energy), 
high-ca (1.8%), α-lactalbumin 
(18% of energy)
d07041804m 
(research diets inc.)
ii
β-lactoglobulin high-fat (60% of energy), 
high-ca (1.8%), 
β-lactoglobulin 
(18% of energy)
d07041803m
 (research diets inc.)
ii
lactoferrin high-fat (60% of energy), 
high-ca (1.8%), lactoferrin 
(18% of energy)
d07041805m 
(research diets inc.) 
ii
lean normal fat (10% of energy), 
normal ca (0.6%), not a 
purified diet, i.e. protein 
source cannot be separated 
(soy, maize, wheat etc.) (18% 
of energy)
2018s (harlan) 
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4.3 methods
4.3.1 body weight and body fat measurements
Body weight was monitored weekly during the weight gain period and one 
to two times per week during the calorie restriction period using a stand-
ard table scale (Ohaus Scout™ Pro, SP4001, Nänikon, Switzerland). The 
consumption of feed per cage was monitored daily using the same table 
scale. Body fat content was analysed by dual-energy X-ray absorptiometry 
(DEXA, Lunar PIXImus, GE Healthcare, Chalfont St. Giles, UK) at the 
end of the weight gain, weight loss and weight re-gain phases.
4.3.2  collection and analysis of faecal samples  
 (studies i, ii and iv)
At end of the weight gain, weight loss and weight re-gain periods, the mice 
were housed in metabolic cages for 72 hours. All faeces were collected dur-
ing housing in the metabolic cages. Fat content of the faecal samples was de-
termined by the SBR (Schmid-Bondzynski-Ratzlaff) method (International 
standart 1986), modified for faecal sample analysis and the calcium content 
was determined using the ICP-MS (inductively-coupled plasma mass spec-
trometry) (Elan 6100, Perkin Elmer, Boston, MA, USA). The apparent 
fat absorption was calculated from the amount of feed consumed and the 
amount of fat excreted during housing in the metabolic cages. The appar-
ent fat absorption (%) was determined as 100 x [(fat intake - faecal fat)/(fat 
intake)].
4.3.3  calorimetry and metabolic performance   
 (study iv)
The possibility of different dietary proteins influencing metabolic perform-
ance, energy expenditure, physical activity as well as drinking and feeding 
behaviour, was analysed by housing a group of animals (n=4/whey and 3/ca-
sein group) in a home cage-based monitoring system for laboratory animals 
(LabMaster®, Bad Homburg, Germany). The mice were housed in this sys-
tem over 7 subsequent days after 5 days of adaptation to the system and the 
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study diets in identical training cages. The instrument consists of highly 
sensitive feeding and drinking sensors for automated online measurement, 
a calorimetry system that determines O2 consumption, CO2 production, 
and respiratory quotient (RQ = VCO2 / VO2, where V is volume), respiratory 
exchange rate and a heat and photobeam-based activity monitoring system 
which detects and records every ambulatory movement.
4.3.4 collection of the tissue samples
At the end of each treatment period, the mice were rendered unconscious 
withCO2 /O2 (95%/5%) (AGA, Riihimäki, Finland), and decapitated. The 
blood samples were taken in plastic tubes and the serum separated by centrif-
ugation at +4ºC for 15 minutes. The livers (Study IV) and the subcutaneous, 
epididymal, abdominal and retroperitoneal fat pads (Studies II, III and IV) 
were removed, washed with saline, blotted dry and weighed. Tissue samples 
were snap-frozen in liquid nitrogen and stored at -80ºC until assayed.
The samples for histology and immunohistochemistry were fixed in 
10% formaline and embedded in paraffin with routine techniques (Stud-
ies II and IV). The liver samples for Oil Red O staining were frozen in 
isopentane (-38ºC) and stored at -80ºC until further processed.
4.4 biochemical determinations
4.4.1  blood glucose, serum insulin and serum 
 lipids (studies i, ii and iv)
Blood glucose (Studies I, II and IV) was analysed from the truncal blood 
samples taken straight after sacrificing the animals. Blood glucose was de-
termined by glucometer (Super Glucocard™ II, GT-1630, Arkray Factory 
Inc., Shiga, Japan).
Serum insulin (Study IV) was determined by ELISA kit for mouse insu-
lin (Ultra sensitive Mouse Insulin ELISA kit 90080, Crystal Chem Inc., 
IL, USA).
Serum lipids (Study I) were analysed by an accredited laboratory, 
HUSLAB, Helsinki University Central Hospital, Helsinki, Finland (Hi-
tachi 912 Automatic Analyser, Hitachi Ltd., Tokyo, Japan).
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4.4.2 serum 1,25(oh)2d3 and pth (study i)
The serum 1,25(OH)2D3 was determined by RIA-kit (IDS Ltd, Boldon, 
UK) and serum intact PTH was determined by ELISA (Immutopics Inc., San 
Clemente, CA, USA) according to the instructions of the manufacturer.
4.5  histology, immunohistochemistry  
 and adipocyte cross-sectional area
4.5.1 histological analysis (study iv)
Sections (4 μm) of paraffin-embedded liver samples were cut with a mi-
crotome, stained with standard haematoxylin/eosin staining and examined 
with a light microscopy. The severity of the observed lesions was graded 
according to Herbert et al. (2002).
The relative amount of lipids in the liver samples was determined from 
Oil Red O stained frozen sections (4 μm) with AnalySIS Pro -software 
(Soft Imaging System, Münster, Germany).
4.5.2  immunohistochemical staining of f4/80   
 (study iii)
As a marker of macrophage infiltration into the adipose tissue, sections 
(5 μm) of paraffin-embedded adipose tissue samples were stained for the 
expression of F4/80 with an anti-F4/80 monoclonal antibody (F4/80 
antibody [CI:A3-1] ab6640, Abcam, Cambridge, UK) according to the 
indirect peroxidase-conjugated streptavidin procedure. Three different 
microscope fields were analyzed for each individual mouse adipose depot. 
The total number of nuclei and the number of nuclei of F4/80-express-
ing cells were counted for each field. The fraction of F4/80-expressing 
cells for each sample was calculated as the sum of the number of nuclei of 
F4/80-expressing cells divided by the total number of nuclei in sections 
of a sample.
57materials and methods
4.5.3  adipocyte cross-sectional area 
 (studies ii and iii)
Adipocyte cross-sectional area was determined for each adipocyte in three 
(Study III) to six fields (Study II) per sample using Leica QWin Standard 
software (Leica Microsystems Imaging Solutions Ltd, Cambridge, UK).
4.6  microarray procedure and gene 
 expression analysis (study iii)
4.6.1 microarray procedure
Five μg of RNA from the epididymal fat pads of two control mice, and 
of two high-calcium whey protein-fed mice were reverse-transcribed to 
cDNA, hybridised according to the standard protocol with Mouse Ge-
nome 430 2.0 array (Affymetrix) and scanned with GeneChip Scanner 
3000 (Affymetrix). The complete data set is available from the NCBI’s 
Gene Expression Omnibus (GEO) database and the gene expression 
profiling data comply with the MIAME standard (accession number 
GSE9280).
4.6.2 data processing
The data were pre-processed with the robust multichip algorithm (RMA) 
(Irizarry et al. 2003), normalised per chip to the median, and analyzed 
with Genespring 7.2. (Agilent, USA). The genes detected to be present 
in the data from all four microarrays were passed to further analysis. Dif-
ferentially expressed probe sets were selected based on filtering by the fold 
change (+/- 1.2-fold). The lists of the obtained up- and down-regulated 
probe sets were inspected for the enriched Gene Ontology (GO) terms 
and the KEGG pathways among the genes by using the "David 2006" pro-
gram (Dennis et al. 2003), and the genes were clustered based on the GO 
terms in order to detect possible subgroups of co-expressed genes with 
certain functions using the “TAFFEL” (Kurki et al. 2008).
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4.6.3 gene expression analysis
The increased expression of leptin and β
3
 adrenergic receptor (Adrb3) 
in the adipose tissue of high-calcium whey protein-fed mice was veri-
fied by quantitative real-time PCR. One μl of cDNA was subjected to a 
quantitative real-time polymerase chain reaction by the LightCycler in-
strument (Roche diagnostics, Neuilly-sur-Seine, France) for detection of 
leptin, Adrb3 and 18S mRNAs. The 18S served as a housekeeping gene. 
The quantities of leptin, Adrb3 and 18S PCR products were quantified 
with an external standard curve amplified from purified PCR product in 
the presence of 0.5 μM of the following primers: leptin forward AGAC-
CGGGAAAGAGTG, reverse GCCATAGTGCAAGGTT; Adrb3 forward 
ACCAACGTGTTCGTGACT, reverse CAGCTAGGTAGCGGTCCA; 
18S forward ACATCCAAGGAAGGCAGCAG, reverse TTTTCGTCAC-
TACCTCCCCG.
4.7 liver metabolomic profile (study iv)
In order to detect energy restriction-induced changes in hepatic metabo-
lism, the metabolomic profiling of liver samples was performed. Char-
acterisation of changes in lipid species was performed with a lipidomic 
strategy using ultra performance liquid chromatography coupled to mass 
spectrometry (UPLC/MS). Additionally, a set of 13 primary metabolites 
(glucose-6-phosphate, fructose-6-phosphate, mannose-6-phosphate, 
fructose bisphosphate, glycerate-3-phosphate, ribose-5-phosphate, suc-
cinate, malate, citrate, pyruvate, phosphoenolpyruvate, 6-phosphogluco-
nate and fumarate) was analysed in order to investigate the changes in en-
ergy metabolism. The analysis was conducted by high performance liquid 
chromatography tandem mass spectrometer (HPLC/MS/MS).
4.8 statistical analysis
Data are presented as mean ± SEM. Statistically significant difference in 
mean values were tested by ANOVA, followed by Tukey’s test excluding the 
microarray and metabolomics data. Statistical analyses of metabolomics 
data (Study IV) were performed using the R statistical software (www.r-
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project.org), and a Welch type t-test was used to analyse the microarray 
data (Study III). 
P-values below 0.05 were considered statistically significant. The 
GraphPad Prism, version 4.02 (GraphPad Software, Inc., San Diego, CA, 
USA) and SPSS, version 10.1 (SPSS Inc. Chicago, IL, USA) were used for 
the statistical analyses.
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5 results
5.1 body weight
5.1.1 weight gain (study i)
The effect of dairy proteins and calcium on weight gain differed signifi-
cantly depending on the type of dairy protein (Figure 3). The addition of 
calcium in the casein-based diet did not affect weight gain during the 21-
week treatment period, but high calcium intake combined with whey pro-
tein inhibited weight gain (p<0.05). The final body weight in the High-
Ca Whey group (44.1±1.1g) was 7.9% lower than in the High-Ca group 
(47.9±1.0g) and 8.3% lower than in the Control group (48.1±0.8g).
5.1.2 weight loss (study ii, iv and unpublished data)
Weight loss was induced by a 30% energy restriction from the ad libitum 
energy intake. In Study II, the whey protein components (α-lactalbumin, 
β-lactoglobulin and lactoferrin) enhanced weight loss in comparison with 
the Control diet (p<0.001), whereas the weight loss in the High-Ca Whey 
group did not reach statistical significance (Figure 3). In Study IV how-
ever, the High-Ca Whey diet accelerated weight loss significantly in com-
parison with the Control diet (p<0.001). The High-Ca or Whey diets did 
not induce significant enhancement of weight loss.
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5.1.3 weight re-gain (study ii)
Even though whey protein-containing diets efficiently inhibited weight 
gain and accelerated weight loss, they were not able to attenuate the sig-
nificant increase in body weight resulting from the ad libitum feeding after 
energy restriction (Figure 3).
Figure 3. Difference in mean body weight in comparison with the Control 
group (%).
5.2  amount of adipose tissue and 
 adipocyte size
5.2.1 weight gain (study i and iii)
The body fat content of the mice increased significantly during the weight 
gain phase. However, when high calcium intake was combined with whey 
protein, the increase in body fat content was significantly smaller (p<0.05) 
63results
than in the High-Ca and Control groups (Figure 4). In addition, the 
mean adipocyte cross-sectional area was significantly smaller in the High-
Ca Whey group than in the Control group (7458±147 μm2 vs. 8012±156 
μm2, p=0.01) at the end of the weight gain period.
Figure 4. Difference in mean fat percentage in comparison with the Con-
trol group (%).
5.2.2 weight loss (study ii and iv)
In addition to attenuating fat tissue gain, the High-Ca Whey diet also in-
creased the fat tissue loss during weight loss (Figure 4). From the whey 
protein components, α-lactalbumin and lactoferrin increased the loss of 
fat tissue significantly in comparison with the Control diet (p<0.001), the 
fat percentage of the Lactoferrin group (24.5±1.6%) being even signifi-
cantly lower than the fat percentage of the High-Ca Whey (31.0±1.9%) and 
the β-lactoglobulin (30.4±1.2%) groups (p<0.05) after weight loss. Even 
though the mean fat percentage in the High-Ca and Whey groups reached 
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the same level than in High-Ca Whey group, the reduction in fat percent-
age during weight loss was only significant in High-Ca Whey group.
The localisation of fat tissue loss was evaluated by weighing the fat pads 
(subcutaneous, epididymal, abdominal and perirenal). Weight loss ef-
fectively reduced the weight of the fat pads in all groups except for the 
epididymal fat, which was reduced significantly only in the α-lactalbumin 
(p<0.01) and Lactoferrin groups (p<0.001) (Figure 5). In Study IV, the 
High-Ca Whey diet significantly increased the reduction of all the fat pads 
in comparison with the Control group, whereas the effect of the High-Ca 
or Whey diets was not statistically significant.
Figure 5. The decrease in mean fat pad weight during weight loss in com-
parison with the mean fat pad weight before weight loss (%).
Adipocyte size after weight loss was analysed only in Study II. In the Con-
trol (4583±276 μm2) and β-lactoglobulin (4045±220 μm2) groups adi-
pocyte size was not significantly different from the values obtained before 
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weight loss (5340±400 μm2). However, adipocyte size after weight loss was 
significantly decreased in the α-lactalbumin (2381±209 μm2, p<0.001 vs. 
before weight loss), Lactoferrin (3147±284 μm2, p<0.05 vs. before weight 
loss) and High-Ca Whey (3824±408 μm2, p<0.01 vs. before weight loss) 
groups. Also the distribution of adipocyte size varied between the groups, 
the variation in size being greatest before weight loss and after weight loss 
in the Control group.
5.2.3 weight re-gain (study ii)
During the weight re-gain phase, the body weight of the mice returned to 
the level observed before weight loss. However, the amount of body fat was 
from 4.4±6.6% (Lactoferrin group) to 15.3±3.7% (α-lactalbumin) lower 
after weight re-gain (ANOVA p-value 0.331). The fat pad weights revealed 
that the α-lactalbumin diet significantly inhibited the accumulation of vis-
ceral fat during weight re-gain (p<0.05).
The adipocyte size increased in all of the groups during the weight re-
gain phase. The largest adipocytes after weight re-gain were found in the 
Control group (5337±359 μm2) while the size of adipocytes was slightly, 
but non-significantly, smaller in the High-Ca Whey (4879±454 μm2), 
α-lactalbumin (4567±204 μm2), β-lactoglobulin (4407±175 μm2) and 
Lactoferrin groups (4391±336 μm2) (ANOVA p-value 0.232). Also the 
distribution of adipocyte size was more similar between the groups after 
weight re-gain than after weight loss.
5.3  energy intake and metabolic 
 performance
There were no differences in energy intake between the groups in any of 
the studies. The mean ad libitum energy intake during weight gain (13.4±0.2 
kcal/mouse/day in the High-Ca Whey; 13.3±0.5 kcal/mouse/day in the 
High-Ca and 12.5±0.01 kcal/mouse/day in the Control group, ANOVA 
p-value 0.290, Study I) was slightly, but not significantly, lower than the 
mean energy intake during weight re-gain (14.0±0.02 kcal/mouse/day in 
α-lactalbumin, 12.6±0.4 kcal/mouse/day in the β-lactoglobulin, 15.0±1.1 
kcal/mouse/day in the Lactoferrin, 15.2±1.2 kcal/mouse/day in the High-
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Ca Whey and 14.1±0.6 kcal/mouse/day in the Control group, ANOVA p-
value 0.419).
In order to investigate the differences in drinking and feeding be-
haviour, activity and metabolic performance, the groups of Control and 
High-Ca Whey diet-fed mice were housed in a home cage-based monitor-
ing system. A 7-day monitoring did not reveal differences in cumulative 
feed or water intake, respiratory exchange rate, heat production, O2 con-
sumption, CO2 production, total or rearing activity or ambulatory move-
ments during the observation period.
5.4 fat absorption
The effect of different diets on fat excretion was analysed and the appar-
ent fat absorption calculated based on the fat intake and fat excretion data. 
The fat absorption in the Control group did not differ significantly be-
tween the studies or between the weight gain, weight loss or weight re-gain 
phases (Table 6). The fat absorption in the High-Ca Whey group varied 
between 96.1±0.9% in the weight gain (Study I) and 98.0±0.3% in the 
weight re-gain phase (Study II), which resulted in a significant difference 
in comparison with the Control group in some (Studies I and IV), but not 
all studies (Study II). The addition of calcium in the study diets decreased 
fat absorption significantly in some, but not all, of the studies.
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5.5  blood glucose and serum insulin  
 (studies i, ii and iv)
Blood glucose was measured at the end of the weight gain (Studies I and 
IV), weight loss (Studies II and IV) and weight re-gain phases (Study II). 
The changes in body weight did not alter blood glucose significantly in the 
Control group either in Study II or Study IV. Weight loss on the High-Ca 
Whey diet resulted in significantly decreased blood glucose level in Study 
IV (p<0.001 in comparison with the values observed before weight loss) 
but not in Study II. The level of serum insulin was also significantly low-
ered as a result of weight loss in the High-Ca Whey (p<0.01 in comparison 
with the values observed before weight loss and energy restricted Control 
group) but not in the Control group (Study IV).
5.6 adipose tissue gene expression (study iii)
In order to investigate the effects of the High-Ca Whey diet on adipose 
tissue metabolism, the gene expression profiling of epididymal adipose 
tissue was carried out using the Affymetrix Mouse Genome 430 2.0 array. 
The microarray analysis of two representative samples per group (Con-
trol and High-Ca Whey) revealed significant changes in the expression of 
129 genes, with a similar amount of up- and down-regulated genes in the 
High-Ca Whey group. The largest number of up-regulated genes was en-
riched in insulin signalling pathway, which contained five reporters with 
over 1.2-fold changes and fourteen genes with a smaller or insignificant 
difference in the expression. The second largest number of up-regulated 
genes was found in the adipocytokine signalling pathway, the down-regu-
lated genes being clustered in the fatty acid metabolism pathway.
Based on the expression data and the pathways associated with altered 
genes, two interesting up-regulated genes that may transmit alterations of 
metabolism in the fat tissue were identified in the microarray data. The pu-
tative targets were adrenergic β
3
-receptor  and leptin, which could be related 
to the inhibition of fat tissue gain in the High-Ca Whey group. The qRT-
PCR analysis revealed a significant, 2.3-fold up-regulation (p=0.0002) in 
the expression of adrenergic β
3
-receptor in the High-Ca Whey group vs. the 
Control, and 2.1 times greater leptin mRNA expression (p=0.02).
69results
5.7 liver (study iv)
5.7.1 liver histology
With a view to investigating the potential mechanisms by which dairy prod-
ucts might lower the risk of insulin resistance and type 2 diabetes, the ef-
fect of weight loss on liver histology and fat accumulation was studied. The 
effect of weight loss on the Control diet was compared to that on the High-
Ca whey diet.
After weight loss, the fat droplets were smaller and mainly present in the 
perivenular regions, while slight to severe macrovesicular fatty change of 
a diffuse pattern was observed in the obese mice. Minimal foci of inflam-
matory cells and necrotic hepatocytes were occasionally noted after weight 
loss, but fibrosis was absent.
Oil Red O staining revealed that weight loss significantly reduced hepatic 
lipid accumulation independent of the diet, even though the amount of lip-
ids still failed to reach the level observed in the lean mice. Oil Red O staining 
demonstrated that weight loss on the Control and High-Ca Whey diet sig-
nificantly reduced hepatic lipid accumulation (40.5±3.3% before weight loss 
vs. 23.8±3.5% in the Control and 17.5±2.9 in the High-Ca Whey group) and 
lipid droplet size (348.9±75.7, 98.9±18.6 and 58.8±7.8 arbitrary units be-
fore weight loss and in the Control and High-Ca Whey group, respectively), 
but the amount of fat did not reach the level observed in the lean mice (lipid 
accumulation 4.4±1.2% and lipid droplet size 21.3±1.3 arbitrary units).
5.7.2 liver metabolomic profile
UPLC/MS and HPLC/MS/MS -based metabolomic platforms were used to 
asses the effect of weight loss on liver metabolomic profile. Samples from 
the Control (n=10) and High-Ca Whey (n=10) weight loss groups were 
analysed and the results were compared against the Lean group (n=10) as 
well as the samples from animals that were sacrificed before weight loss 
(n=10, Obese group).
Weight loss significantly reduced the amount of triacylglycerols (TAG) 
(p>0.05 in the Control and p<0.01 in the High-Ca Whey vs. values before 
weight loss) and ceramides (p<0.05 in the Control and p<0.001 in the High-
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The primary metabolite analysis revealed that weight loss on the High-
Ca Whey diet was associated with significant increase of succinate, belong-
ing to the TCA cycle, and of ribose-5-phosphate, a product of the pentose 
phosphate pathway. The High-Ca Whey diet also decreased the level of 
glycolytic metabolites: glucose-6-phosphate, fructose-6-phosphate and 
fructose bisphosphate in contrast with weight loss on the control diet, 
which did not affect the level of these metabolites. The overall effect of 
the treatments on primary metabolite pathways is presented in Table 7 and 
Figure 7.
table 7. concentrations of primary metabolites in liver samples (nmol/g tissue).
energy restriction
the effect of high-ca 
whey in comparison 
with control
lean obese control   high-ca whey
data are presented as mean±sem (n=10/group). means without a common letter differ (p<0.05).
glucose-6-phosphate    28.6±2.7a    19.2±3.5b,c    22.7±1.7a,b    11.2±3.2c    
fructose-6-phosphate    7.0±0.7a    4.9±0.6a,b    6.9±0.7a    3.2±0.9b    
mannose-6-phosphate    1.7±0.2a    1.7±0.2a    1.4±0.1a    0.8±0.2b    
fructose bisphosphate    3.2±0.6a,b    8.7±2.0b,c    9.5±2.4c    0.5±0.1a    
glycerate-3-phosphate    26.2±3.7a    21.0±0.8a,b    17.4±1.2b    13.1±1.4b     
ribose-5-phosphate    0.3±0.02a    0.7±0.1b    0.7±0.1b    1.3±0.1c   
succinate    24.5±3.3a    5.3±1.1b    6.7±2.4b    24.0±4.0a   
malate    42.0±5.2a    54.5±3.7a,b    61.3±4.7b    40.5±5.1a   
citrate    4.9±0.7a    2.0±0.3b    1.6±0.2b    1.8±0.3b     
pyruvate    5.6±0.8a    0.9±0.2b    2.6±0.4b    1.5±0.3b     
phosphoenolpyruvate    2.8±0.8a    2.3±0.3a    1.4±0.2a    1.2±0.2a      
6-phosphogluconate    3.5±0.2a,b    2.4±0.2c    3.7±0.2a    2.6±0.4b,c      
fumarate    9.6±1.0a    10.4±1.1a    17.8±1.7b    11.9±1.3a    
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6 discussion
Previous epidemiological and experimental studies have shown that dairy 
intake has beneficial effects on body weight and the amount of body fat. 
Population studies have also indicated that increased dairy consumption 
lowers the risk of developing insulin resistance and type 2 diabetes. How-
ever, the mechanisms and other potential active components other than 
calcium, are not well known. Moreover, the effectiveness and mechanisms 
of calcium intake on body weight is a highly controversial area of research. 
This study investigated the effects of dietary intake of calcium and dairy 
proteins on body weight and fat tissue in an experimental model of diet-
induced obesity. The potential effects of dairy protein and calcium intake 
on liver metabolism, the central element in the development of metabolic 
syndrome and type 2 diabetes, was also studied.
6.1 methodological aspects
animal model
The animal model used in these studies is a well-established model of diet-
induced obesity (Surwit et al. 1988, Collins et al. 2004, Koza et al. 2006). 
The C57Bl/6J mouse strain is often used as a healthy control animal and 
as a basis for genetically modified animal models (Rivera and Tessarol-
lo 2008). When fed a standard laboratory rodent chow, the mean body 
weight of these mice stays below 35g and the body fat percentage is on 
average 25% (Denier et al. 2008). Therefore, this mouse strain serves as a 
better model of typical human obesity than other widely used commercial 
obese mouse models, such as ob/ob (leptin-deficient) or db/db (leptin-
resistant), which are characterised by hyperphagia (Carroll et al. 2004). 
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Despite the wide use of C57Bl/6J mice in obesity research, the exact mech-
anisms explaining their weight gain are not completely understood. The 
weight gain cannot be simply explained by changes in energy intake (Lin et 
al. 2000, Collins et al. 2004, Koza et al. 2006). Other mechanisms, such as 
reduced locomotor activity (Bjursell et al. 2008), decreased leptin (Surwit 
et al. 1997) and β
3
-adrenergic responsiveness (Collins et al. 1997, Collins et 
al. 1999) and altered Wnt signalling (Koza et al. 2006), are likely to explain 
part of the obesity-prone phenotype in these mice.
The length of the weight gain period in the current studies is relatively 
long when compared with what has been reported in the literature (Zemel 
et al. 2000, Sun and Zemel 2004a, 2006). This ensures that at the end 
of the weight gain phase, the mice have significantly higher body weight 
and more body fat than the parallel group of mice on a low-fat diet (un-
published data, Study I), and that the effects really indicate obesity, not a 
normal growth of the animals. This has not always been the case in previ-
ous studies on dietary calcium intake and body weight (Sun and Zemel 
2004a).
composition of the study diets
In all of the studies, the mice were fed with a high-fat diet in order to 
induce obesity. The protein source and calcium content of the high-fat 
diet was modified. The amount of protein in the diet (18% of energy) was 
the same as in a standard laboratory chow (Harlan Teklad 2018, Harlan 
Holding, Inc., Wilmington, DE, USA) in all of the diets. Thus the effects 
of the diets are not confounded by an increase in protein intake, which is 
known to affect body weight and the amount of fat tissue (Halton and Hu 
2004). In these experimental diets, all protein was replaced by the protein 
of interest. This approach clearly separates the effects of different protein 
sources and helps to distinguish between the potential differences in the 
proteins in an experimental setting. However, the obvious disadvantage of 
this setting is that the relative amount of a certain dietary protein type is 
only a fraction of this in real-life conditions.
Since calcium intake is suggested to explain at least part of the effect of 
dairy intake on body weight (Zemel 2001), we studied the effect of whey 
and casein in both low- (0.4%) and high-calcium (1.8%) diets. In case of 
77discussion
α-lactalbumin, β-lactoglobulin and lactoferrin, the effect of proteins and 
calcium cannot be separated, since these proteins were not studied within 
low-calcium matrices. However, when investigating the effect of dairy-de-
rived components, the presence of calcium in the diet is natural. In milk, 
calcium is mainly integrated with caseins, not whey proteins, but whey-de-
rived peptides are also known to bind calcium (Vegarud et al. 2000). Calci-
um may also interact with various dairy protein-derived peptides and affect 
calcium metabolism and bioavailability (Narva et al. 2004, Jauhiainen and 
Korpela 2007). It can therefore be reasoned that the presence of calcium 
in the diet gives a more reliable estimate on the effects of dairy proteins, 
even though the effect of calcium and protein cannot be separated. 
characterisation of metabolic changes in adipose tissue and 
the liver
Affymetrix microarray procedure was utilised to determine the High-Ca 
Whey diet-induced changes in adipose tissue. Microarrays provide a prac-
tical approach for screening the expression of thousands of genes simulta-
neously (Schena et al. 1995). Since the understanding of calcium and whey 
protein intake-activated pathways in adipose tissue is scarce, the genome-
wide screening provides a good basis for creating hypothesis of the possible 
mechanisms. The microarray procedure was performed with the high-ac-
curacy Affymetrix Mouse Genome 430 2.0 array (Alberts et al. 2007) with 
two representative samples per group in order to avoid the possible bias 
resulting from pooling the samples before hybridisation (Mary-Huard et 
al. 2007). However, the restricted number of replicates is the principal 
limitation of the microarray results (2/group), and consequently the re-
sults should be interpreted with caution. Despite the fact that the use of 
an inbred and highly homogenous animal model under strictly control-
led research conditions decreases inter-individual variation in the results, 
the enormous data matrices produced by the microarray method inevita-
bly contain noise and uncertainty, which have to be filtered and modified 
by different computer-based techniques. This also limits the accuracy of 
interpreting significant results and, without further confirmation of the 
results with traditional techniques, such as qRT-PCR, the results can only 
be considered preliminary.
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Hepatic lipid and primary metabolite profile was investigated by two high-
throughput metabolomic platforms. A UPLC/MS-based method was used 
for screening the lipid species and an HPLC/MS/MS-based platform for 
the detection of primary metabolites. MS-based methods are considered 
sensitive for characterising, identifying, and quantifying a large number of 
compounds in a biological sample in which metabolite concentrations might 
cover a broad range (Kaddurah-Daouk et al. 2008). Metabolomics, even 
though a novel technique, is seen as a particularly valuable tool especially in 
the area of nutrition (Whitfield et al. 2004) and multifactorial diseases, such 
as obesity and metabolic syndrome (Griffin and Nicholls 2006). Neverthe-
less, the most critical shortcoming of the method is the limited identification 
of spectral peaks and the lack of universal metabolomic databases.
Taken together, the present study has been conducted by us-
ing a wide array of methods suitable for the research question. 
The animal model and study design are appropriate for inves-
tigating the effect of nutritional components in complex dis-
eases, such as obesity and metabolic syndrome. Furthermore, 
the long duration of the interventions corresponds well with 
the chronic nature of the diseases. Novel methods have been 
utilised in studies for screening the genome- and metabo-
lome-wide effects of dairy proteins but especially microarray 
analysis may have benefited from having a larger number of 
replicates.
6.2  effect of dairy proteins and calcium 
  intake on body weight and the   
 amount of adipose tissue
Effect of protein type
Dairy proteins have been postulated to explain the more pronounced effect 
of dairy on body weight in comparison with calcium supplementation (for 
review, see Zemel 2004, 2005). However, the effect of dairy proteins on 
body weight has not been compared prior to the present study. The cur-
rent results indicate that whey proteins and especially α-lactalbumin and 
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lactoferrin have body weight and body composition -modulating proper-
ties when administered in combination with a high-calcium diet. 
Whey proteins may suppress food intake in humans by increasing satiety 
(Hall et al. 2003, Anderson et al. 2004, Bellissimo et al. 2008), but no dif-
ferences in the food intake of the mice were detected between the treatment 
groups in this study. The amino acid composition of whey proteins or the 
substantial amount of branched-chain amino acids has often been sug-
gested to explain their health effects (for review, see Ha and Zemel 2003, 
for review, see Yalcin 2006). Especially an increased intake of leucine, 
which stimulates muscle protein synthesis (Stipanuk 2007) and has a role 
as an energy substrate, may be beneficial in the treatment of obesity and 
metabolic syndrome (for review, see Layman and Walker 2006, Zhang et al. 
2007b). The amount of leucine in the High-Ca Whey diet was nearly 1.5-
fold in comparison with the Control diet, and leucine intake may explain 
the differences in body weight and fat between these two groups. However, 
the amount of leucine in the High-Ca Whey diet was 1.2 to 1.3-fold great-
er than in the α-lactalbumin and Lactoferrin diets which enhanced weight 
loss more effectively than the High-Ca Whey protein diet. This suggests 
the effect of whey proteins on body weight and fat tissue to be dependent 
on factors other than leucine intake alone.
Whey protein-derived bioactive peptides have also been hypothesised 
to mediate the body weight-regulating effects of dairy proteins. Dairy-de-
rived peptides have beneficial effects for example on blood pressure (for 
review, see Jauhiainen and Korpela 2007), bone metabolism (Narva et al. 
2007) and gastrointestinal health (for review, see Severin and Wenshui 
2005), and therefore the peptide hypothesis serves as an appealing expla-
nation in the field of obesity as well. Bioactive peptides are formed dur-
ing digestion in the gastrointestinal tract, but the precise peptide profile 
which is absorbed after the intake of different dairy proteins, remains un-
known. Detecting the potential peptides with adipose tissue metabolism-
modulating properties would require the development of a specific pep-
tidomics platform (Schulz-Knappe et al. 2005) for postprandial peptides 
of dairy origin. Currently, the key focus of peptidomics platforms is still 
on the identification of endogenous peptides (Schrader and Selle 2006, 
Tammen et al. 2007) and thus the identification of potential dairy-derived 
anti-obesity peptides represents a major challenge.
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effect of calcium intake
The findings of this study support the previous epidemiological and clini-
cal evidence of the body weight-modulating effect of dairy intake. How-
ever, in this series of studies the role of dietary calcium was not in line with 
previous experimental data. The High-calcium diet did not significantly 
inhibit weight gain or enhance weight loss in contrast to earlier find-
ings (Zemel et al. 2000, Shi et al. 2001a, Parra et al. 2007), and the role of 
1,25(OH)2D3  in the regulation of body weight was not supported by the 
results of this study. Instead, the current findings give more evidence to 
the hypothesis that whey proteins are a source of body weight-modulating 
components (for review, see Zemel 2005).
The discrepancy between the findings of this study and the previous 
experimental results may be influenced by the animal model. The data 
from Zemel and co-workers are based on experiments on aP2-agouti-
transgenic mice. This mouse expresses the agouti gene in adipose tissue un-
der the control of aP2-promoter and thus resembles human adipocytes in 
the expression pattern of the agouti gene (Mynatt et al. 1997). The agouti 
protein stimulates calcium influx into the adipocytes as well as the expres-
sion and activity of fatty acid synthase (Jones et al. 1996, Xue and Zemel 
2000). Similarly to other mice, the C57Bl/6J-mice lack the expression 
of agouti in their adipocytes and hence the basal expression and activity of 
fatty acid synthase are likely to differ from those in aP2-agouti-transgenic 
mice. Since fatty acid synthase expression and activity represent a key vari-
able in the 1,25(OH)2D3 -centered theory on the body weight-regulating 
effect of calcium, the aP2-agouti-transgenic mice might be more sensitive 
to the effects of calcium.
Increased faecal fat excretion has been suggested to explain at least part 
of the effects of calcium and dairy on body weight. This study confirmed 
that high-calcium diets have an effect on fat excretion resulting in a small, 
and in some circumstances significant, reduction of fat absorption. In ad-
dition, these results pointed out the importance of measuring the fat in-
gestion during faecal collection, a variable which has not been determined 
in all of the studies (Jacobsen et al. 2005, Boon et al. 2007b, Lorenzen et 
al. 2007). Even though fat absorption was decreased in the High-Ca Whey 
group and not in the High-Ca group during weight gain, an equivalent 
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difference between these diets was not seen in all of the studies. Neither 
consistent differences in the fat absorption between the individual whey 
protein components during weight loss and weight re-gain were detected. 
Hence the question of why dairy calcium affects fat absorption more ef-
ficiently than supplemental calcium (Lorenzen et al. 2007) cannot be an-
swered by the effect of dairy proteins.
To summarise, whey protein-containing high-calcium diets 
inhibited body weight gain and accumulation of fat tissue. 
Whey protein-containing high-calcium diets also accelerated 
body weight and fat tissue loss during energy restriction in 
high-fat-fed C57Bl/6J mice. Calcium supplementation alone 
did not significantly affect body weight or the amount of fat tis-
sue. High-calcium diets decreased fat absorption slightly in-
dependent of the protein source of the diet, which augments, 
but does not fully explain, the effect on body weight. The ami-
no acid content of whey proteins and the amount of leucine 
may play a role in the effects on body weight, but the significant 
enhancement of weight loss on the α-lactalbumin and lacto-
ferrin diets cannot be explained by the leucine content of the 
diets. The formation of anti-obesity bioactive peptides during 
protein digestion is a plausible, yet unverified, possibility and 
an interesting area of future research.
6.3  effect of dairy proteins and calcium  
 on adipose tissue and the liver
adipose tissue gene expression
Microarray analysis revealed significant changes in the expression of 129 
genes, with similar amount of up- and down-regulated genes in the High-
Ca Whey group in comparison with the Controls. The qRT-PCR analysis 
confirmed the significant up-regulation of the β
3
-adrenergic receptor and 
leptin expression in the High-Ca Whey diet-fed mice. Interestingly, the 
expression of the β
3
-adrenergic receptor is down-regulated in response to 
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high-fat feeding in C57Bl/6J mice (Collins et al. 1997, Collins et al. 1999, 
Moraes et al. 2003), which is considered to be one of the factors contrib-
uting to diet-induced obesity. Leptin expression has also been found to 
be decreased in these mice in comparison with obesity-resistant mouse 
strains (Surwit et al. 1997, Watson et al. 2000). Thus, the High-Ca Whey 
diet showed a protective effect against high-fat diet-induced decline of the 
β
3
-adrenergic receptor expression and corrected the leptin expression in 
the direction normally seen in an obesity-resistant mouse strain. These 
changes are likely to contribute to the inhibition of weight gain. The sig-
nificant up-regulation of leptin and the β
3
-adrenergic receptor expression 
is also connected with the insulin signalling pathway, which was enriched 
with the up-regulated genes. 
Whey protein intake has been associated with insulin metabolism al-
ready previously, but this study showed the effect of whey protein on the 
level of adipose tissue gene expression for the first time. In comparison 
with casein, whey protein has a greater post-prandial insulinotropic effect 
(Nilsson et al. 2004, Tessari et al. 2007) resulting from the rapid amino 
acid absorption, the substantial amount of certain insulinotropic amino 
acids (leucine, isoleucine, valine, lysine, threonine) and the inhibition 
of dipeptidyl peptidase IV in the intestine, which leads to an increased 
concentration of incretin hormones, glucose-dependent insulinotropic 
polypeptide and glucagon-like peptide-1 (Gunnarsson et al. 2006, Nils-
son et al. 2007). It is also of note that an increase in adipocyte size results 
in increased insulin resistance, at least in vitro (Olefsky 1977, Molina et al. 
1989). Thus, smaller adipocyte size in the High-Ca Whey group could also 
partly explain the clustering of up-regulated genes in the insulin signalling 
pathway.
The development of adipose tissue insulin resistance limits the trig-
lyceride storage capacity of adipose tissue, which results in ectopic fat ac-
cumulation in non-adipose tissue (for review, see Lewis et al. 2002). This, 
in turn, leads to a complex array of metabolic abnormalities characteris-
tic of insulin-resistant states. The sensitisation of insulin and adipocy-
tokine signalling pathways as a result of the High-Ca Whey diet represents 
a mechanistic link between an increased intake of dairy products and a 
lower risk of metabolic syndrome and type 2 diabetes (Pereira et al. 2002, 
Azadbakht et al. 2005, Choi et al. 2005, Liu et al. 2005, Liu et al. 2006, Mi-
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zoue et al. 2006, van Dam et al. 2006, Elwood et al. 2007). In line with this, 
the serum insulin and blood glucose values were improved to the level of 
healthy controls during weight loss on the High-Ca Whey diet but not on 
the Control diet. However, the lowering effect on blood glucose was not 
seen consistently in all of the studies.
liver metabolism
The liver lipidomic and primary metabolite profile was investigated after 
weight loss. In accordance with the previous studies, we found increased 
levels of triacylglycerols, diacylglycerols and specific ceramide species and 
observed down-regulation of sphingomyelins in the obese mice (Yetukuri 
et al. 2007). Weight loss on the High-Ca Whey diet significantly increased 
the level of sphingomyelins and decreased the level of diacylgycerol, re-
storing the relative level of ceramides and diacylglycerols to the level of 
lean animals. The accumulation of both ceramides and diacylglycerols in 
peripheral tissues contribute to insulin resistance (Stratford et al. 2004, 
Summers 2006, Holland et al. 2007b, Zhang et al. 2007a) and lowering ce-
ramide levels in obese rodents, in particular, has been shown to ameliorate 
insulin resistance and prevent the onset of diabetes (Holland et al. 2007a). 
Therefore, the decrease of these lipids can be considered particularly ben-
eficial. The level of the analysed primary metabolites was particularly af-
fected in the High-Ca Whey group. Energy restriction in normal-weight, 
healthy mice enhances hepatic gluconeogenesis (Hagopian et al. 2003, 
Selman et al. 2006) and suppresses glycolysis (Dhahbi et al. 1999). The level 
of primary metabolites indicated that this effect was pronounced in the 
High-Ca Whey group, together with an enhanced flux through the pentose 
phosphate pathway. The metabolic changes in the liver were accompanied 
by a decrease in hepatic lipid content, which was clearly, but not signifi-
cantly, greater in the High-Ca Whey than in the Control group.
Lipid accumulation in the liver is currently considered to be one of the 
cornerstones in the development of insulin resistance and metabolic syn-
drome (for review, see Yki-Järvinen 2005, for review, see Kotronen and 
Yki-Järvinen 2007). These results clearly suggest that a High-Ca Whey 
diet may beneficially modulate the hepatic lipid profile targeting specifi-
cally the lipotoxic ceramide and diacylglyceride species.
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Taken together, these results demonstrate that a High-Ca Whey 
diet has beneficial effects on both adipose tissue and liver me-
tabolism. The microarray data suggest sensitisation of insulin 
signalling as a result of High-Ca Whey feeding, which, in theo-
ry, limits the ectopic fat storage. Together with the less lipotoxic 
and diabetogenic hepatic lipid profile, these findings provide 
a novel mechanistic link to explain the epidemiological find-
ings which support the role of increased dairy intake in the 
prevention of metabolic syndrome and type 2 diabetes. Since 
the microarray findings are based on only two representative 
samples per group, they should be interpreted with caution.
6.4 clinical relevance
The aim of obesity treatment in health care is to prevent and treat other 
chronic diseases, such as type 2 diabetes, metabolic syndrome and hy-
pertension (Finnish Current Care guidelines, 2006). The goal in obes-
ity treatment is a permanent 5-10% weight loss, whereby the significantly 
lower body weight by 5 to 10% in the High-Ca Whey group after weight 
gain and weight loss corresponds well with the current recommendations. 
However, the results of an animal experiment are not by any means di-
rectly applicable to a clinical situation. In the clinical studies investigating 
the effect of dairy products on weight loss, the amount of weight loss in the 
high dairy group has been nearly two-fold in comparison with the controls 
(Zemel et al. 2004, Zemel et al. 2005a, Zemel et al. 2005b). In these stud-
ies, subjects in the high dairy group have been given yogurt or some other 
type of traditional dairy products in which whey proteins account for 20% 
of the milk proteins (Fox and McSweeney 1998). The results of this study 
suggest that increasing the amount of whey proteins could enhance the ef-
fect of a high dairy diet.
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7 summary and conclusions
The present study investigated the effects of dairy protein and calcium in-
take in the prevention and treatment of diet-induced obesity as well as 
the associated effects on adipose tissue and liver metabolism in order to 
characterise the potential mechanisms explaining the reduction of the risk 
for metabolic syndrome and type 2 diabetes that have been reported in 
previous observational studies. 
The main findings of the present study are as follows:
1. obesity
• The intake of calcium in combination with whey protein inhibits weight 
and fat gain and accelerates weight and fat loss in high-fat diet-fed 
C57Bl/6J mice. α-lactalbumin was the most beneficial protein showing 
significantly accelerated fat and weight loss and significantly reduced 
amount of visceral fat after weight re-gain period.
•     The intake of calcium slightly decreases fat absorption, but this does not 
fully explain the results on body weight and body fat. A whey protein-
containing high-calcium diet modifies the adipose tissue gene expres-
sion, having a protective effect against a high-fat diet-induced decline 
of β
3
-adrenergic receptor expression and increase of leptin expression. 
These changes are likely to contribute to the inhibition of weight gain.
2. adipose tissue and liver metabolism
•    A High-Ca Whey diet modifies the metabolism of both adipose tissue 
and the liver. The potential sensitisation of insulin signalling in adi-
pose tissue, together with the less lipotoxic and diabetogenic hepatic 
lipid profile suggest a mechanistic link to explain the epidemiological 
findings on increased dairy intake in the prevention of metabolic syn-
drome and type 2 diabetes.
summary and conclusions
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